Our Resident Network
Meet Our Residents
LabCentral has generated significant interest from entrepreneurs and startups working on groundbreaking science who are eager to join LabCentral, a first-of-its-kind, fully resourced and equipped life-sciences laboratory space. Participants are chosen through a competitive process, where only the highest-potential applicants are selected in keeping with our mission.
AbscoTx is developing a proprietary, injectable, intratumoral drug delivery platform based on research out of the Traverso lab at MIT/BWH and Interventional Radiology at MGH. Our technology acts as a personalized "cancer vaccine" by training the immune system to fight solid cancers both locally and at distant metastatic sites. This therapy modifies the local tumor microenvironment and can elicit a strong, targeted immune response against any type of solid tumor, without causing systemic toxicities ($111B market, CAGR 11%, lead indication in metastatic colorectal cancer).
We solve challenges with previous intratumoral therapies -- such as high drug leakage out of the tumor, lack of image guidance to confirm delivery, and the need for frequent repeat injections -- using an injectable and imageable thermoresponsive polymer that solidifies in the tumor, ensuring precise and sustained drug retention. Our approach works with standard interventional radiology techniques, enabling treatment of advanced-stage tumors anywhere in the body. Unlike CAR-T cells or antibody-drug conjugates, our approach generates a robust immune response against multiple tumor antigens, reducing the likelihood of tumor mutations leading to antigen escape and treatment resistance.
Our lead asset results show strong and durable complete response without recurrence in an immunotherapy resistant (MSI-low) dual-tumor colorectal cancer model, with complete resolution of the treated and untreated tumors in responding animals. We can deliver small hydrophobic molecules and biologic agents via our platform, and we are in discussions with potential strategic partners to use their immune stimulant drugs intratumorally with our system. Based on regulatory analysis with Halloran, our lead asset will follow a streamlined 505(b)(2) pathway, with a clear preclinical development path to Investigational New Drug (IND)-clearance within 3 years. Upon clinical approval, we anticipate premium pricing given the lack of curative-intent alternatives in the market (comparator $65-100k/patient for Imlygic for melanoma).
Targeted delivery of RNA medicines to the brain. By silencing the genes that cause harm, we aim to preserve minds, protect memories, and enable our loved ones to live healthier, longer lives.
Built on three pillars
- Next-generation RNA medicines
- Systemic administration and targeted brain delivery
- Precision and prevention to transform CNS treatment
Delivering therapeutics where the body needs them. Directing a drug to the exact tissue that needs it is one of the hardest problems in medicine. We're solving it by decoding the body's glycan code — the sugar-based signatures unique to every tissue. Through high-throughput in silico and in vivo screening, we map tissue glycan signatures at cellular resolution and design peptides that recognize them. We're starting with the brain, the largest unmet need in medicine. Our lead peptide lets subcutaneously injected payloads — peptides, antibodies, mRNA, ASO, siRNA — cross the blood-brain barrier via transcytosis. We're a team of serial entrepreneurs in Cambridge, MA, sprinting toward the clinic.
Solving the signal problem in liquid biopsy
Amplifyer Bio, Inc. is a startup developing technology arising from a collaboration between the labs of Dr. Sangeeta Bhatia, Dr. Chris Love, Dr. Viktor Adalsteinsson, and Dr. Todd Golub at MIT and the Broad Institute. The work has been published in Science and has been presented at leading conferences both in the US and internationally. The company is focused on the development of novel priming agents that in combination with current liquid biopsy diagnostics will optimize test performance. Amplifyers first program will be focused on increasing cfDNA in blood for cancer diagnostics. This will provide both physicians and patients higher quantity and quality of genomic information related to their cancer, with the aim of improving clinical outcomes.
Arpelos is an early-stage biotechnology company developing multivalent biologics to unlock unprecedented potency and selectivity. Arpelos integrates cutting-edge computational and engineering methods to advance a pipeline tackling a range of diseases underpinned by immune dysfunction. Arpelos was founded by pioneers in immunology, multi-omics, and protein engineering from UCSF, Penn, Stanford, and MIT.
To harness innovative protein engineering to dramatically enhance ADC drug delivery, broaden the therapeutic window, and bring more effective and safer treatments to patients.
We aspire to do this through co-engagement with transferrin receptor for improved intracellular drug delivery.
Our R&D plan is currently split into two phases and is focused on building best and first in class ADCs across established and new antigens and building first in class ADCs with expanded payload repertoire. We plan to do this through a combination of experiments run in-house and via CROs. Initial work at the Harvard Life Labs will involve in vitro studies to assess ADC activity, drug delivery, and subcellular localization of drugs inside cancer cells. We will also do affinity and processing studies of unique bispecific constructs.
Basecamp Research trains frontier AI models for therapeutic design. Our EDEN models are trained on BaseData, the world’s largest proprietary evolutionary genomic dataset: over 100 billion novel genes sourced through partnerships in more than 30 countries across all seven continents. We are now rapidly advancing a pipeline of EDEN-designed therapeutics towards clinical development. Headquartered in London, we have offices and labs in Boston.
Coming Soon
BioFeyn is a life sciences company pioneering new forms of nutrient delivery to improve efficiencies for food systems and sustainability. Using proven advancements from human biomedicine, BioFeyn is maximizing the impact of scarce and expensive ingredients to improve animal health, reduce resource use, and minimize waste.
Decoding the human protein interactome for safer, more targeted therapies.
95% of approved medicines target proteins as isolated entities, bluntly turning them on or off.
This modulates protein function globally, across pathogenic and healthy cellular pathways. It’s why essentially all medicines come with side effects.
We target protein interactions.
By targeting protein-protein interactions (PPIs), we aim to modulate only the pathogenic pathway, leaving healthy functions intact.
BrilliantStrings is an early stage medical device company that has developed a breakthrough approach to accelerate healing of damaged connective tissues based on the direct, controlled-delivery of functional protein (e.g. complete human collagen – CHC) to the injury. The company's technology, supported by decades of academic research, has been demonstrated in animals to rapidly restore the strength of torn tendons. There are multiple applications in the orthopedic space, with rotator cuff disease comprising the largest market and our first target indication. The therapeutic can be administered via injection as well as in other formats (e.g. patches). With injection, BrilliantStrings has the ability to treat patients at a very early stage in tendon degeneration where no other competitor has a solution, expanding an already large market considerably. In addition, BrilliantStrings has developed and patented the CRISPR-based method to produce CHC, under extremely favorable economics, eliminating the complicated supply chain logistics of competing technologies.
We discover molecules where biology actually happens.
Bullseye uses directed evolution inside living cells to discover functional molecules against challenging intracellular targets.
Rather than starting with a predefined mechanism or simplified assay, we generate and evaluate molecular diversity directly in cells, selecting for the biological outcome that matters.
While ASO therapeutics have been shown to be effective at treating disease by targeting disease genes at the RNA level intracellularly with long tissue resident half-life, they have been limited in their ability to treat neurological disease as they cannot effectively get across the blood brain barrier.
Centron Bio is transforming the treatment of neurological disorders with genetic medicines that cross the blood brain barrier.
Cha Therapeutics Inc. is an early-stage, privately held, Massachusetts-based biotechnology start-up developing a proprietary epigenetic therapy that improves cancer patient outcomes.
Our mission is to develop groundbreaking drug combinations to treat cancers that have evaded the immune system, particularly those driven by Wnt signaling.
Our unique approach leverages a combination of compounds designed to re-program tumor cells, making them more susceptible to immune checkpoint inhibitors and other immunotherapies.
Unlocking the full potential
of RNA medicine.
Collage Bio is developing a new class of programmable RNA therapeutics. Our platform combines AI-powered design with advanced polynucleotide engineering to enable precise, durable, and tunable control of gene expression. By bridging gene editing and traditional RNA approaches, we are opening a new frontier in programmable medicine.
Conveyor therapeutics aims to be the first company dedicated to expanding the knowledge of ADC design and development to novel payloads, targeting antigens, and indications. We seek to merge people, passion, and science to create therapeutics, which modulate intracellular targets with cellular precision, to restore health and save lives. Our next generation antibody drug conjugate (ADC) platform will expand the use of ADCs beyond oncology and traditional cytotoxic payloads to immunology and immunosuppressive payloads. Conjugating payloads to an antibody offers a way to improve the therapeutic window of a given drug by directing it to the pathological cell type and reducing the level of systemic exposure of the free payload. With a few exceptions, most current generation ADCs are optimized for cell killing, which limits the applicability in areas outside of oncology. Limited development has gone into optimizing ADCs for other functions (e.g. interrupt kinase or transcription factor activity) or to have utility in cell types with lower expression of the targeted antigen.
Corellia launched out of Champions Oncology, a technology-enabled contract research organization, leveraging the world’s largest PDX Atlas and its living bank for AI-enabled target and drug discovery. Corellia is developing a large pipeline of innovative ADCs for patients with high unmet needs, at a pace and efficiency never achieved before.
Corellia launched out of Champions Oncology, a technology-enabled contract research organization, leveraging the world’s largest PDX Atlas and its living bank for AI-enabled target and drug discovery. Corellia is developing a large pipeline of innovative ADCs for patients with high unmet needs, at a pace and efficiency never achieved before.
About Crosslink
Extracellular adenosine triphosphate (eATP) is highly elevated in solid tumors making it a hallmark of cancers. Relative to normal tissue, tumors release eATP at high levels to help them develop and grow.
Crosslink has engineered a modular biologic domain which takes advantage of this difference to assemble therapeutics in tumors. Crosslink’s domain can be applied to virtually any therapeutic modality to improve tumor specific targeting and enhanced activity. We are currently focused on developing first-in-class/best-in-class applications in antibody drug conjugates and radioligand therapies.
DaCapo Brainscience, Inc. is built to create revolutionary, disease-modifying therapeutics for neurological diseases. DaCapo is fusing a unique understanding of biological systems, their induced pluripotent stem cell (iPSC)-based neuronal culture systems, their proprietary analyses of patient databases, and their pioneering AI/ML algorithms to create an integrated platform for disease-definition and target discovery. With this platform, DaCapo Brainscience can identify novel molecular subtypes of disease and corresponding drug targets for synucleinopathies (such as Parkinson's Disease and Lewy Body Dementia) and other neurodegenerative diseases.
ECI Therapeutics, LLC (ECI) is developing products from donated, pathogen-reduced human plasma. ECI's platform leverages serum-like plasma from donated human blood to promote the healing of epithelial (surface cell) disorders such as dry eye disease, ophthalmic burns, and chronic wounds. ECI has been issued robust patents protecting the formulation that combines serum-like plasma with a novel antimicrobial molecule (chitosan) to create products ranging from liquid eye drops to gels, ointments, contact lenses, contoured bandages, and wound dressings.
ECI's initial product will focus on dry eye disease. There are 22 million dry eye patients in the United States and of those only 8 million are treated, with 25% reporting satisfaction with their treatment. There is a need for more effective treatments with fewer side effects. We intend to fill this gap while growing the percent of diagnosed patients seeking treatment.
Epitope has identified specific sequence (epitopes) that lead to the generation of pathogenic antibodies, the underlying driver of a number of auto-immune disorders. Epitope's lead program uses a proprietary peptide display technology that will target and neutralise / eliminate the pathogenic antibodies, supporting patients who suffer Bullous Pemphigoid, a skin condition that one of the companies founders has been researching and treating over several decades.
Research Area:
Drug Discovery / Development
Small Molecules
Evonik's strategic innovation unit and business incubator, Creavis, seeks to establish an innovation satellite to accelerate innovation in life science fields.
Evonik Health Care partners with the world's pharmaceutical, medical device and nutraceutical companies to transform complexity into value. Evonik is a leading system solution provider in nucleic acid-based medicine technologies. Research will include new excipients and delivery platforms to leverage the full potential of mRNA as a new therapeutic modality.
Many of the world’s largest and most innovative biopharmaceutical companies partner with Evonik to optimize their media platforms and processes. Our broad portfolio of cell culture ingredients and related services leverages six decades of industry leadership in highly purified amino acids. Research will include new technology platforms for cell culture media outside of dipeptides.
Evonik corporate venture capital will partner with the research team in Cambridge.
Our aim is to develop a novel domain for immune recruitment for bispecific T cell engagers that specifically recruits immune cells in an activated, cytotoxic state. To do this, we are designing therapeutics that mimic antigens from common infectious diseases. In effect, our therapeutics will direct potent, existing immune responses for an infectious disease (e.g. SARS-CoV-2, influenza) towards a cancer, leading to a more precise and efficacious response.
Unique propriatary platform technologies overcoming current limitations in gene therapy
GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™ (Transcription-Factor-ome, pronounced as tee-eff-ome), to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas.
GelMEDIX is a platform-based company focused on developing bioadhesive hydrogel drug depots to improve patient compliance and treatment outcomes in ophthalmology. GelMEDIX was founded based upon 8 years of academic work originating at Massachusetts Eye and Ear, Harvard Medical School, Northeastern University, and UCLA that was motivated by challenges in post-op and chronic treatment in ophthalmology.
General Biologics, Inc. uses the power of rational biological design to create new classes of therapeutics for treatment of unmet medical needs that have been underserved by the research community and overlooked by investors.
We have used this approach to develop a ground-breaking, first-in-class fusion protein therapeutic for treatment of hypoxia.
Gensaic is a phage-derived particle (PDP) gene delivery platform that addresses key limitations in the current gene therapy landscape. Unlike the market lead AAV technology, PDPs offer durable therapeutic efficacy via repeat administration, enable tissue-specific targeting, support massively scalable manufacturing, and can package any full-length human gene as a therapeutic (>20 kb).
HydroGene has a mission to bring gene therapy to all liver diseases. This can be accomplished with non-viral gene delivery, which would be safe, cheap, and redosable. Unfortunately, non-viral gene delivery with lipid nanoparticles has suffered of inefficiency from nuclear delivery of DNA cargo. As an alternative, HydroGene has solved how to scale hydrodynamic delivery inot the liver of large animals for the first time by leveraging the biliary system. HydroGene's approach is efficient, scalable, and safe in porcine and primate models and has exciting potential to treat rare and common diseases.
InGel Tx technology is an injectable biomimetic hydrogel platform engineered for the sustained release of stem cells and drugs in the eye, initially targeting regenerative medicine for retinitis pigmentosa, macular degeneration and geographic atrophy.
Research Area:
Biological Product
Cell Therapy
Interacta is building the data layer for AI native antibody discovery. While language and vision AI thrive on massive datasets biology is still operating with fewer than 15000 antibody antigen interactions. We are fixing that. Our platform screens over 100 million interactions per week in mammalian cells with functional relevance and at one thousandth the traditional cost.
This is not a CRO. It is a new operating model high quality non exclusive binder datasets across diverse targets ready to fine tune AI models or jumpstart discovery campaigns. We are doing for antibodies what Scale AI did for language and vision fueling the next generation of in silico biology.
Kano Therapeutics believes that innovative drugs need innovative supply chains. Kano is building a bio-infrastructure company to solve the huge bioprocessing capacity crunch in therapeutic manufacturing for cell and gene therapy companies. Kano's immediate focus lies on a new type of genetic vector for CRISPR applications that enables their customers to get their innovative drugs faster in and through clinical trials.
Research Area:
Biological Product
Gene Therapy
Lightcast's platform enables highly multiplexed single cell functional screening with optical control over tens of thousands of droplets with flexible cargos, allowing for droplet merges, imaging, selection and dispense.
Sparking immune regeneration via thymus regeneration.
1. Lightning Bio uses deep knowledge of immune cell generation and bioengineering to restore immunity damaged by toxins, disease, or age
2. Lightning Bio leverages the body's inherent regenerative capacity to create novel therapeutics for immune dysfunction
3. Lightning Bio's science works to replenish T cell diversity through modification of the body's cell factories
Limax Biosciences is developing a strong and flexible hydrogel adhesive for wounds inside and outside the body
Coming Soon
Research Area:
Biological Product
Cell Therapy
Matrisome Bio is developing tools to deliver targeted therapies to the extracellular matrix (non-cellular components) of disease tissues such as tumors and fibrotic lesions in order to convert it from a barrier to a drug depot.
Research Area:
Platform Technology
Drug Delivery
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Their innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors.
Coming Soon
Research Area:
Drug Discovery / Development
Small Molecules
Coming Soon
Research Area:
Drug Discovery / Development
Recombinant Therapeutic Protein
RASyn is developing a suite of integrative technologies, leveraging unparalleled high-throughput sequencing, cell free protein synthesis and functional screening coupled with computational protein design and machine learning. RASyn's platform will power predictive diagnostics analytics, enhance novel target discovery as well as unlock novel therapeutic design spaces across multiple modalities.
For the human body to develop and function normally, the precise level of expression of each gene of the genome needs to be tightly regulated by epigenetics. When this balance is disrupted, alteration in gene expression can lead to severe genetic diseases for which no cure is available.
Regel’s technology utilizes a deactivated Cas system (dCas) which targets the epigenome without editing or damaging the DNA. This approach harnesses the natural mechanisms of gene regulation, allowing for efficient and permanent restoration of normal gene expression.
Research Area:
Biological Product
Gene Therapy
Coming Soon
Ribonaut Therapeutics is developing a novel small molecule platform capable of specifically degrading RNAs for the treatment of human diseases. Ribonaut's approach leverages the work of academic founder, Matthew Disney - Chair of the Department of Chemistry at Scripps Florida, and his foundational insights into the targeted recruitment of RNAses to specific RNA structural motifs using small molecules.
Research Area:
Drug Discovery / Development
Small Molecules
Riboway specializes in controlling how proteins are made by targeting RNA. Our smart RNA-targeting technology enables us to upregulate, downregulate, activate, or inhibit target proteins, depending on therapeutic needs. This flexibility is driven by our AI-based platform that decodes RNA regulation to identify druggable angles. So far, we’ve successfully validated 5 out of 5 targets attempted.
Our pipeline focuses on neurodegenerative diseases, including a first-ever ASO designed to activate protein function. We are currently raising seed funding as well as looking for partnership/BD out-licensing opportunities.
Rubik Therapeutics is developing programmed CAR-T/NK cell therapies for solid tumors. We have identified a set of highly selective, exclusive solid tumor targets as well as T cell modulators that will allow us to treat solid tumors while avoiding toxicity and immune evasion.
Research Area:
Biological Product
Cell Therapy
Stipple Bio is unlocking cellular profiling and target discovery with epitope resolution.
Research Area:
Drug Discovery / Development
Recombinant Therapeutic Protein
Stratagen Bio is developing a novel class of sensors that provide quantitative and direct measurements of tissue oxygen, which are not possible with alternative sensors. Their sensor will enable more personalized and effective treatments for patients in a wide range of applications including oncology, wound healing, and tissue transplantation.
Research Area:
Medical Device
Diagnostic Device
Synolo Therapeutics, an early-stage biotechnology company launched by RA Capital, is pioneering the development of precision-targeted immunotherapies for cancer. Powered by computational protein design and proprietary technologies which yield biological data sets at unprecedented scale and resolution, we are building a pipeline of first-in-class multi-specific biologics with novel functionalities. Synolo was founded by pioneers in the field of protein design and engineering, synthetic biology, DNA sequencing, immunology, and biologics drug discovery and development.
Typewriter's technology will further expand current genome editing toolbox. More importantly, the technology possesses advantages over other existing editing methods and has potentials to address many unmet needs to cure diseases.
Research Area:
Cell & Gene Therapies
Viska.Bio Therapeutics induces Immunogenic Cell Death by treating cancer with a Fusion Protein between a tumor specific antibody and the enzyme Xanthine Oxidase. This produces superoxide in the tumor microenvironment oxidizing lipids which are incorporated into the lysosome which then becomes leaky releasing degradative enzymes which induce endopepsis - or cellular internal digestion. One result is that calreticulin, the eat me signal for DCs, migrates to the cell surface initiating the immunogenic feature. ODIN Therapeutics has produced a fusion protein to EGFR and shown that it produces the classic markers of Immunogenic Cell Death.
Research Area:
Drug Discovery / Development
Recombinant Therapeutic Protein
Volnay is building transformative and commercially viable cell & gene ventures centered on product development and technology innovation.
We build next-generation manufacturing technologies and integrate them with high value therapeutic assets to deliver commercially viable therapeutic products. Our goal is to unleash the full potential of cell and gene therapies for patients worldwide.
WhiteLab Genomics is a pioneering startup leveraging Artificial Intelligence to accelerate and mitigate risks in early-stage research and development pipeline for genomic medicine. We are actively engaged in partnerships with renowned academic institutions (Genethon, Brain Institute), as well as small and mid-sized biotech (Flagship Pioneering, SIREN biotech) and pharmaceutical companies (e.g. Sanofi), aimed at addressing critical challenges in the biopharma industry for target discovery, payload, and vector engineering and bioproduction. We are collaborating with Sanofi to develop new gene therapies in ophthalmology (targeting microglia in the CNS) and rare disease.
By bringing together the power of computer sciences (e.g. ML, GenAI) and biology, we help our partners to reach their target product profile, faster, in leaner ways. We have developed a proprietary platform including algorithms and databases to improve the design of therapeutic candidates for enhanced safety and efficacy. It includes vectors optimisation such as adeno-associated virus (AAV) and lentivirus, or non-viral like LNP. WLG synergistically combines in-house biomarker cellular atlas, computer science techniques with bioinformatic methods like transcriptomic analysis and structure prediction. WLG employs computational and structural biology to predict the most pertinent receptor-ligand interactions for specific targets, be it organs or cells. For instance, in the context of improved AAV transduction, WhiteLab strives to identify membrane-associated receptors and ligands that are highly specific to a tissue as a potential target. A key differentiator regarding our approach is that we can identify biomarkers that are highly specific to a cell type in over 850 cells in the body. This enables our AI platform to design the best vector to bring the right therapeutic sequence into the cells expressing a specific phenotype.